AR049354A1 - VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN - Google Patents

VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN

Info

Publication number
AR049354A1
AR049354A1 ARP050102434A ARP050102434A AR049354A1 AR 049354 A1 AR049354 A1 AR 049354A1 AR P050102434 A ARP050102434 A AR P050102434A AR P050102434 A ARP050102434 A AR P050102434A AR 049354 A1 AR049354 A1 AR 049354A1
Authority
AR
Argentina
Prior art keywords
hpv
vaccinacontra
preparation procedure
human papilomavirus
human
Prior art date
Application number
ARP050102434A
Other languages
English (en)
Spanish (es)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0413510.9A external-priority patent/GB0413510D0/en
Priority claimed from US11/114,301 external-priority patent/US20050287161A1/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR049354A1 publication Critical patent/AR049354A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP050102434A 2004-06-16 2005-06-14 VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN AR049354A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413510.9A GB0413510D0 (en) 2004-06-16 2004-06-16 Vaccine
US11/114,301 US20050287161A1 (en) 2002-12-20 2005-04-26 Vaccine

Publications (1)

Publication Number Publication Date
AR049354A1 true AR049354A1 (es) 2006-07-19

Family

ID=35160037

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102434A AR049354A1 (es) 2004-06-16 2005-06-14 VACUNACONTRA PAPILOMAVIRUS HUMANO(VPH) Y PROCEDIMIENTO DE PREPARACIoN

Country Status (18)

Country Link
EP (1) EP1758609B1 (enExample)
JP (1) JP2008502633A (enExample)
KR (1) KR20070029254A (enExample)
AR (1) AR049354A1 (enExample)
AU (1) AU2005253723B2 (enExample)
BR (1) BRPI0512042B8 (enExample)
CA (1) CA2566620C (enExample)
FR (2) FR15C0082I2 (enExample)
IL (1) IL179138A0 (enExample)
LU (3) LU92900I2 (enExample)
MA (1) MA28692B1 (enExample)
MX (1) MXPA06014515A (enExample)
NO (1) NO20070195L (enExample)
PE (1) PE20060434A1 (enExample)
PL (1) PL1758609T3 (enExample)
RU (1) RU2420313C2 (enExample)
SG (1) SG153837A1 (enExample)
WO (1) WO2005123125A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
HRP20141063T1 (hr) * 2008-07-31 2015-01-02 Glaxosmithkline Biologicals S.A. Cjepivo protiv hpv
MX2011013566A (es) * 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
CN103119168A (zh) * 2010-07-15 2013-05-22 不列颠哥伦比亚癌症局分支机构 人乳头瘤病毒e7抗原组合物及其用途
SG11201501623PA (en) 2012-10-30 2015-05-28 Redvax Gmbh Recombinant particle based vaccines against human cytomegalovirus infection
JP6663438B2 (ja) * 2014-10-24 2020-03-11 エイチピーブイヴァックス, リミテッド ライアビリティー カンパニー.Hpvvax, Llc. 癌および皮膚病変の治療
CN107188966B (zh) 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
KR101361769B1 (ko) * 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신

Also Published As

Publication number Publication date
CA2566620C (en) 2014-03-11
BRPI0512042B8 (pt) 2021-05-25
KR20070029254A (ko) 2007-03-13
LU92898I2 (fr) 2016-03-08
MXPA06014515A (es) 2007-03-23
WO2005123125A1 (en) 2005-12-29
AU2005253723A1 (en) 2005-12-29
LU92900I2 (fr) 2016-03-08
FR15C0082I2 (fr) 2016-10-28
EP1758609B1 (en) 2012-10-03
BRPI0512042B1 (pt) 2019-01-22
CA2566620A1 (en) 2005-12-29
PE20060434A1 (es) 2006-06-08
LU92899I2 (fr) 2016-03-08
NO20070195L (no) 2007-01-15
PL1758609T3 (pl) 2013-02-28
FR15C0082I1 (fr) 2016-01-08
FR15C0084I2 (fr) 2016-10-28
JP2008502633A (ja) 2008-01-31
SG153837A1 (en) 2009-07-29
RU2420313C2 (ru) 2011-06-10
AU2005253723B2 (en) 2011-01-20
IL179138A0 (en) 2007-03-08
MA28692B1 (fr) 2007-06-01
BRPI0512042A (pt) 2008-02-06
RU2006143804A (ru) 2008-08-20
EP1758609A1 (en) 2007-03-07
FR15C0084I1 (enExample) 2016-01-08

Similar Documents

Publication Publication Date Title
ATE497770T1 (de) Pharmazeutische formulierungen von decitabin
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
AR109263A2 (es) Composición que comprende moxidectina
HN2003000196A (es) Derivados de indolinfenilsulfonamida
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
ECSP066959A (es) Compuestos macrociclicos como inhibidores de la replicación viral
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
ECSP045300A (es) Antígenos virales
UY27465A1 (es) Métodos y composiciones para tratar flavivirus y pestivirus con 4' modificaciones nucleosides
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
CR8207A (es) Un conjugado citotoxico ca6 antigeno- especifico y metodos para utilizar el mismo
AR035293A1 (es) Composicion oftalmica.
CU20090112A6 (es) Compuestos macrocíclicos como inhibidores de la replicación viral
UY31403A1 (es) "derivados novedosos de ({((3-metilfenil)-2h-tetrazol-5-il)-etoxi} -4h-1,2,4-triazol-3-il), composiciones farmacéuticas conteniendolos y uso médico de los mismos".
AR042530A1 (es) Vacuna que comprende particulas viroides del virus papiloma humano 16 y 18
PE20110677A1 (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
WO2007063421A3 (en) Compositions and methods relating to treatment of cancer and infectious diseases
UA93004C2 (ru) Композиция для вагинального применения
SE0300098D0 (sv) Use of cyclin D1 inhibitors
UY29181A1 (es) Derivados de bencenosulfonamidas n-sustituidos, composiciones que los contienen, procesos de preparación y aplicaciones
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
PE20060434A1 (es) Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph

Legal Events

Date Code Title Description
FA Abandonment or withdrawal